SRDX vs. OFIX, ANGO, ARAY, CTSO, ATRC, ATEC, BVS, PLSE, IRMD, and SIBN
Should you be buying Surmodics stock or one of its competitors? The main competitors of Surmodics include Orthofix Medical (OFIX), AngioDynamics (ANGO), Accuray (ARAY), Cytosorbents (CTSO), AtriCure (ATRC), Alphatec (ATEC), Bioventus (BVS), Pulse Biosciences (PLSE), Iradimed (IRMD), and SI-BONE (SIBN). These companies are all part of the "surgical & medical instruments" industry.
Orthofix Medical (NASDAQ:OFIX) and Surmodics (NASDAQ:SRDX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation, community ranking and media sentiment.
89.8% of Orthofix Medical shares are held by institutional investors. Comparatively, 96.6% of Surmodics shares are held by institutional investors. 4.7% of Orthofix Medical shares are held by company insiders. Comparatively, 8.9% of Surmodics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Orthofix Medical presently has a consensus target price of $18.00, suggesting a potential upside of 23.71%. Surmodics has a consensus target price of $57.00, suggesting a potential upside of 64.88%. Given Orthofix Medical's stronger consensus rating and higher probable upside, analysts clearly believe Surmodics is more favorable than Orthofix Medical.
Orthofix Medical received 74 more outperform votes than Surmodics when rated by MarketBeat users. However, 67.13% of users gave Surmodics an outperform vote while only 61.80% of users gave Orthofix Medical an outperform vote.
Orthofix Medical has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, Surmodics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.
Surmodics has lower revenue, but higher earnings than Orthofix Medical. Orthofix Medical is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Surmodics had 13 more articles in the media than Orthofix Medical. MarketBeat recorded 16 mentions for Surmodics and 3 mentions for Orthofix Medical. Orthofix Medical's average media sentiment score of 0.70 beat Surmodics' score of 0.62 indicating that Surmodics is being referred to more favorably in the news media.
Surmodics has a net margin of 9.44% compared to Surmodics' net margin of -16.64%. Orthofix Medical's return on equity of 13.30% beat Surmodics' return on equity.
Summary
Surmodics beats Orthofix Medical on 14 of the 17 factors compared between the two stocks.
Get Surmodics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SRDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Surmodics Competitors List
Related Companies and Tools
